Watch | OncLive

Trending Videos

Pancreatic Cancer Treatment Advances Call for a Renewed Focus on the Role of Liposomal Irinotecan: With Jennifer B. Valerin, MD, PhD

Pancreatic Cancer Treatment Advances Call for a Renewed Focus on the Role of Liposomal Irinotecan: With Jennifer B. Valerin, MD, PhD

Commentary

An Ophthalmologist Guides Oncologists and Patients Through ADC-Related Eye Toxicities: With Sara Nunnery, MD, MSCI; and Sarah Sunshine, MD

An Ophthalmologist Guides Oncologists and Patients Through ADC-Related Eye Toxicities: With Sara Nunnery, MD, MSCI; and Sarah Sunshine, MD

Commentary

FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS

FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS

Commentary

FDA Approval Insights: Iberdomide-Based Therapy Adds Another Option for R/R Myeloma: With Sagar Lonial, MD, FACP, FASCO

FDA Approval Insights: Iberdomide-Based Therapy Adds Another Option for R/R Myeloma: With Sagar Lonial, MD, FACP, FASCO

Commentary

Dissecting Diagnostic and Management Factors in Systemic Mastocytosis

Dissecting Diagnostic and Management Factors in Systemic Mastocytosis

Commentary

Biomarker-Driven Shifts Signal the Next Generation of mCRC Therapies: With Tanios S. Bekaii-Saab, MD

Biomarker-Driven Shifts Signal the Next Generation of mCRC Therapies: With Tanios S. Bekaii-Saab, MD

Commentary

Positioning PD-L1/VEGF Bispecifics in First-Line Non–Small Cell Lung Cancer: With Solange Peters, MD, PhD

Positioning PD-L1/VEGF Bispecifics in First-Line Non–Small Cell Lung Cancer: With Solange Peters, MD, PhD

Commentary

Precision Oncology, Bispecific Antibodies, and Next-Generation Targeted Therapies Are Reshaping NSCLC Care: With Chandler Park, MD; Stephen V. Liu, MD

Precision Oncology, Bispecific Antibodies, and Next-Generation Targeted Therapies Are Reshaping NSCLC Care: With Chandler Park, MD; Stephen V. Liu, MD

Commentary

Breaking Down the FDA Approval of Zanidatamab-Based Regimens in HER2+ Gastric Cancer

Breaking Down the FDA Approval of Zanidatamab-Based Regimens in HER2+ Gastric Cancer

Commentary

INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management

INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management

Commentary

Shorts

Erika Hamilton, MD

Highlighting the FDA Approval of Maintenance Tucatinib-Based Therapy in Advanced HER2+ Breast Cancer

21 hours ago

by

Erika P. Hamilton, MD

Vincent Chung, MD

Spotlighting the Potential Future of Pancreatic Cancer Combination Regimens

2 days ago

by

Vincent Chung, MD

Brian M. Wolpin, MD, MPH

Highlighting Daraxonrasib’s Survival Benefit in Metastatic Pancreatic Cancer

2 days ago

by

Brian M. Wolpin, MD, MPH

Binod Dhakal, MD

The Potential Utility of Allogeneic CAR T-Cell Therapy in Myeloma

2 days ago

by

Binod Dhakal, MD

Alexis Ann LeVee, MD

Previewing the lidERA Trial PRO Data Being Presented at ESMO 2026

3 days ago

by

Alexis LeVee, MD

Kevin Kalinsky, MD, MS, FASCO

Previewing Breast Cancer Insights Expected at ESMO 2026

6 days ago

by

Kevin Kalinsky, MD, MS

Milana V. Dolezal, MD

Exploring Changes in First-Line Treatment for HER2-Positive Breast Cancer

8 days ago

by

Milana Dolezal, MD, MSci

Matthew Kurian, MD

Emphasizing the Importance of Vigilance When Using AI in Oncology

8 days ago

by

Matthew Kurian, MD

Leo Rasche, MD

Exploring Talquetamab-Based Therapy Before Transplant in Multiple Myeloma

9 days ago

by

Leo Rasche, MD

Sagar Lonial, MD, FACP, FASCO

Examining Iberdomide Plus Daratumumab/Dexamethasone in R/R Multiple Myeloma

9 days ago

by

Sagar Lonial, MD, FACP, FASCO

Expert Conversations

OncChats

Peer Exchange

OncLive Insights

Shows & Podcasts

How This Is Building Me

Two Onc Docs

Oncology Unplugged With Dr Chandler Park

Cancer, Character, and Calling

From Discovery to Delivery: Charting Progress in Gynecologic Oncology

Breast Cancer Briefing

News & Analysis

OncLive News Network®

OncLive TV

Rapid Readouts

Biomarker Consortium

Trending on OncLive

FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer

FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer

September Roundup of FDA Approvals in Oncology: 8 Decisions to Know

FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC

Individualized Neoantigen Vaccine Elicits Durable T-Cell Responses in Resected HPV– HNSCC